ArticleScientific reports2017
The positivity of estrogen receptor and progesterone receptor may not be associated with metastasis and recurrence in epithelial ovarian cancer.
Article in Scientific reports, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 1 synthesis or guideline pooled it, 46 citations in OpenAlex.
- A Systematic Review of Atypical Endometriosis-Associated Biomarkers.International journal of molecular sciences · 2022Pooled it
- Association of hormone receptor-based pathological features with prognosis in high-grade serous ovarian carcinoma: a retrospective cohort study and nomogram construction.Journal of ovarian research · 2026Article
- Signaling Pathway Dissection After Progesterone Receptor Enhancement in an Immortalized Pre-Cancer Fallopian Tube Epithelial Cell Line.International journal of molecular sciences · 2026Article
- Transcriptomic Analysis of Hub Genes Reveals Associated Inflammatory Pathways in Estrogen-Dependent Gynecological Diseases.Biology · 2024Article
- Correlation of clinicopathological and prognostic characteristics between endometriosis-associated and primary ovarian cancer.BMC cancer · 2023Article
- Reevaluating the Role of Progesterone in Ovarian Cancer: Is Progesterone Always Protective?Endocrine reviews · 2023Article
- Dysregulation of Cholesterol Homeostasis in Ovarian Cancer.Current oncology (Toronto, Ont.) · 2023Review
- Hormone-Dependent Cancers: New Aspects on Biochemistry and Molecular Pathology.International journal of molecular sciences · 2023Article
- A comprehensive immunohistochemical analysis of 26 markers in 250 cases of serous ovarian tumors.Diagnostic pathology · 2023Article
- Spatial Transcriptomic Analysis of Ovarian Cancer Precursors Reveals Reactivation of IGFBP2 during Pathogenesis.Cancer research · 2022Article
- Molecular Management of High-Grade Serous Ovarian Carcinoma.International journal of molecular sciences · 2022Review
- Article
- A risk prediction model of gene signatures in ovarian cancer through bagging of GA-XGBoost models.Journal of advanced research · 2021Article
- [ENTPD5 gene is highly expressed in epithelial ovarian cancer: analysis based on Oncomine database and bioinformatics].Nan fang yi ke da xue xue bao = Journal of Southern Medical University · 2021Article
- Oleuropein is a natural inhibitor of PAI-1-mediated proliferation in human ER-/PR- breast cancer cells.Breast cancer research and treatment · 2021Article
- New insights into the functions of progesterone receptor (PR) isoforms and progesterone signaling.American journal of cancer research · 2021Review
- A Review of the Clinical Characteristics and Novel Molecular Subtypes of Endometrioid Ovarian Cancer.Frontiers in oncology · 2021Review
- Four and a Half LIM Domains 2 (FHL2) Contribute to the Epithelial Ovarian Cancer Carcinogenesis.International journal of molecular sciences · 2020Article
- Association of benign gynaecological diseases and risk of endometrial and ovarian cancers.Journal of Cancer · 2020Article
- Triple stimulation (TriStim) before bilateral oophorectomy in a young woman with ovarian cancer: a case report and review of the literature.Fertility research and practice · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The estrogen (ER) or progesterone receptors (PR) is positively associated with better clinical outcomes in ovarian cancer. Whether metastasis or recurrence of ovarian cancer is correlated with this association has not been investigated. Data on 894 women with epithelial ovarian cancer were collected and the association between ER or PR positivity and peritoneal or lymph node metastases or recurrence was analysed. ER or PR positivity was higher in high-grade, low-grade serous and endometrioid carcinoma, but lower in mucinous and clear-cell carcinoma. Significantly higher ER or PR positivity was seen in endometrioid carcinoma or high-grade serous carcinoma with peritoneal metastases, respectively, but not other subtypes. In addition, there was no significant difference in ER or PR positivity between cases with and without lymph node metastasis in these five subtypes. In recurrent high-grade serous carcinoma with peritoneal metastases (n = 103), the positivity of ER or PR was 86% and 55% respectively. Our data demonstrate that the association between ER or PR positivity and peritoneal metastases was only seen in endometrioid or high grade serous carcinoma, respectively. There was no association of ER or PR positivity and lymph node metastases. The majority of recurrent high-grade serous carcinoma with peritoneal metastases (86%) were ER positive.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.